Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 5, 2021 - Issue 2
Journal homepage
140
Views
0
CrossRef citations to date
0
Altmetric
Case Reports

Effectiveness of subcutaneous tocilizumab in refractory adult Still’s disease: report of three cases and a review of the literature

Masataka Torigoea Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City, Oita, Japan;b Department of Rheumatology, National Hospital Organization, Beppu Medical Center, Beppu City, Oita, Japan
,
Keisuke Maeshimaa Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City, Oita, JapanCorrespondence[email protected]
,
Yuhei Kuriyamaa Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City, Oita, Japan
,
Itomi Abea Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City, Oita, Japan
,
Takashi Ozakia Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City, Oita, Japan
,
Yuichi Omuraa Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City, Oita, Japan
,
Tatsuhito Umekia Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City, Oita, Japan
,
Chiharu Imadac Department of Rheumatology, Oita Red Cross Hospital, Oita City, Oita, Japan
,
Koji Ishiic Department of Rheumatology, Oita Red Cross Hospital, Oita City, Oita, Japan
&
Hirotaka Shibataa Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City, Oita, Japan
 show all
Pages 365-370 | Received 14 Oct 2020, Accepted 28 Jan 2021, Published online: 15 Apr 2021

References

  • Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
  • Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603–618.
  • Mimura T, Kondo Y, Ohta A, et al. Evidence-based clinical practice guideline for adult Still’s disease. Mod Rheumatol Taylor and Francis Ltd. 2018;28(5):736–757.
  • Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmunity. 2018;93:24–36.
  • Didion SP. Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature. IJMS. 2017;18(12):2563.
  • Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis. 2000;59 (Suppl 1):i21–i27.
  • Mitrovic S, Fautrel B. New markers for adult-onset Still's disease. Joint Bone Spine Elsevier Spine. 2018;85(3):285–293.
  • Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: a meta-analysis. Mod Rheumatol. 2018;28(5):849–857.
  • Li T, Gu L, Wang X, et al. A pilot study on tocilizumab for treating refractory adult-onset Still’s disease. Sci Rep. 2017;7(1):7.
  • Sakai R, Nagasawa H, Nishi E, et al. Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol. 2012;31(3):569–574.
  • Vandemergel X, Vandergheynst F. Efficacy of low-dose tocilizumab on relapsing adult-onset Still's disease. Acta Medica (Hradec Kralove). 2016;59(1):22–25.
  • Bannai E, Yamashita H, Kaneko S, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease. Mod Rheumatol. 2016;26(2):297–301.
  • Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial . Ann Rheum Dis. 2018;77(12):1720–1729.
  • Ogata A, Atsumi T, Fukuda T, et al.; the Musashi Study Investigators. Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res John Wiley and Sons Inc. 2015;67(10):1354–1362.
  • Iwamoto N, Fukui S, Umeda M, et al. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis. Mod Rheumatol. 2016;26(5):662–666.
  • Ogata A, Kato Y, Higa S, et al. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv. 2019;16(6):639–648.
  • Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum. 2010;62(8):2530–2535.
  • Puéchal X, DeBandt M, Berthelot J-M, et al.; Club Rhumatismes Et Inflammation. Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken). 2011;63(1):155–159.
  • Reihl Crnogaj M, Čubelić D, Babić A, et al. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review. Rheumatol Int. 2020;40(8):1317–1325.
  • Abdallah H, Hsu JC, Lu P, et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57(4):459–468.
  • Nakashima Y, Kondo M, Miyahara H, et al. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab. Drug Des Dev Ther. 2014;8:913–919.
  • Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (London, England). 2008;371(9617):987–997.
  • Fechtenbaum M, Lasselin-Boyard P, Salomon S, et al. Decrease of tocilizumab dose in patients with rheumatoid arthritis: a pilot study. Pharmacology S. Karger AG. 2016;98:73–78.
  • Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40(6):768–780.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.